Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02115243
Title Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Duke University
Indications

melanoma

Therapies

Ipilimumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.